Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVR106 (Spunoleucel) in Post-Transplant Respiratory Viral Infections
NCT04933968Phase 2Terminated
- Sponsor
- AlloVir
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ALVR106 in respiratory syncytial virus infection (RSV), influenza, human metapneumovirus infection (HMPV), parainfluenza virus infection, sponsored by AlloVir. Started Mar 2022; status: terminated.
02
Drugs
ALVR106
03
Conditions
respiratory syncytial virus infection (RSV)influenzahuman metapneumovirus infection (HMPV)parainfluenza virus infection
Beyond the preview
Go deeper on NCT04933968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933968.